Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity

In Vitro Cytotoxic‐Active Platinum(II) Complexes Derived from Carboplatin and Involving Purine Derivatives

“…[11,13] The bands observed for 1-6 in the 150-600 cm -1 region, with maxima at 540-545 and 554-563 cm -1 , could be assigned to the ν(Pt-N) and ν(Pt-O) stretching vibrations, respectively. [14] The presence of these two vibrations in the far-FTIR spectra indirectly confirmed the coordination of both types of organic ligands, that is, HL 1 -HL 6 and cbdc, to the central Pt II atom. As can be seen from the data given in the Exp.…”

“…The seven novel [Pt(cbdc) ( II atom is tetracoordinated to two unidentate N-donor carrier ligands derived from 6-benzylamino-2-chloro-9-isopropylpurine (HL 1 -HL 6 ) and the bidentate Odonor cyclobutane-1,1-dicarboxylate dianion (cbdc). Multinuclear and two-dimensional NMR studies proved the N-7 atom to be the coordination site of the HL n ligands, which was also confirmed by single-crystal X-ray analysis of the [Pt(cbdc)(dmso)(HL 7 )]·H 2 O (7a·H 2 O) intermediate.…”

“…[10] The synthetic strategy is given in Scheme 1. The molecules of HL 1 -HL 6 were characterized by elemental analysis, meltingpoint determination and FTIR, Raman and NMR ( 1 H, 13 C and 15 N) spectroscopy. The results can be found in the Supporting Information.…”

“…[5] These types of organic compounds have formerly been used in the synthesis of metallocomplexes, including platinum(II) and platinum(IV) complexes. Compounds cis-[PtCl 2 [6] and references cited therein). The best results were obtained for cis-[PtCl 2 (ros) 2 ], the IC 50 (concentration of the tested compound lethal for 50 % of cells) values of which were equal to 1 µ for the K-562 (chronic myelogenous leukaemia), G-361 (malignant melanoma) and HOS (osteogenic sarcoma) human cancer cell lines and to 2 µ for the MCF7 (human breast adenocarcinoma) cells.…”

Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands

“…The synthesis and characterization of tested [Pt(ox)(L n ) 2 ]·xH 2 O (1-7) and [Pd(ox)(L n ) 2 ]·xH 2 O (8-14) involving N6-benzyl-9-isopropyladenine derivatives (L n ; Scheme 1) were recently reported [5][6][7]. Although the in vitro cytotoxicity was recently screened by an MTT assay against HOS (1-8, 10, 12-14) and MCF7 (1-7) cells and by acetoxymethyl assay against K562 and MCF7 (9, 11), we decided to broaden the number of human cancer cell lines for the following tests [ovarian carcinoma (A2780), ovarian carcinoma cisplatin resistant cells (A2780cis), malignant melanoma (G361), breast adenocarcinoma (MCF7), lung carcinoma (A549), osteosarcoma (HOS) and cervix epitheloid carcinoma (HeLa)], mainly in connection with the previous promising results.…”